Background/Objectives: The use of collagenase for enzymatic wound debridement has been studied extensively and has been established as the standard of care for nonhealing and necrotic wounds in individuals for whom surgical intervention is not an option. Collagenase has been shown to be effective in adults but has been studied in a limited capacity in infants and neonates. The purpose of this study was to investigate the use of collagenase in the neonatal intensive care unit (NICU). Methods: Retrospective chart review of infants and neonates admitted to the NICU at Arkansas Children's Hospital with nonhealing wounds for which collagenase was used for wound healing over a 1-year time period. Six wounds were identified: five surgical wound dehiscence and one intravenous infiltrate. Results: Before the use of collagenase, five of the six wounds had been treated with an alternative dressing. Once collagenase was initiated, three of these wounds reached complete granulation and closure in less time than in the episode of prior therapy. The number of days to reach 100% granulation once treated with collagenase was 5 to 18 days (mean 12.2 days). Surgical intervention for the debridement and closure of these wounds was not required, providing cost savings to the patient. Daily wound care was completed with negligible pain recordings. Conclusion: The use of collagenase for enzymatic debridement can be beneficial, safe, and effective for the treatment of nonhealing and necrotic wounds in infants and neonates.
Pediatric wounds are a potential complication in the care of medically fragile children. Common causes of these wounds are trauma, burns, adverse pressure, surgery, surgical wound dehiscence, and intravenous infiltrate (1, 2) . The use of collagenase for enzymatic wound debridement has been studied extensively and has been established as the standard of care for chronic, nonhealing wounds in individuals for whom surgical intervention is not an option (3, 4) . A large percentage of wounds initially treated to promote autolytic debridement do not progress well through the natural stages of wound healing, especially in individuals with significant medical complications in whom surgical strategies for wound debridement are not possible or are unfavorable. In these situations, significant amounts of nonviable tissue develop, impeding the wound healing process (1, 5) . Clostridium collagenase (Santyl, Smith & Nephew, Fort Worth, TX) is the only enzymatic debriding ointment that the U.S. Food and Drug Administration has approved (6) . Collagenase selectively targets collagen debris in necrotic tissue that is bound to the wound bed, without affecting keratin, fat, or fibrin (3) (4) (5) . Faster wound healing, fewer days to granulation, promotion of cell migration, greater selectivity, less pain, and less overall need for surgical intervention are outcomes associated with the use of collagenase for wound debridement (3, 4, 7) . The use of collagenase has occasionally produced a transient erythema in surrounding tissues when the ointment has been applied outside the wound area, with one case of systemic hypersensitivity reported after 1 year of collagenase treatment (8) .
The use of collagenase for wound care has been examined largely in adults (3) (4) (5) (6) (7) (8) (9) and in a limited number of studies in children. A study by Ozcan et al (10) in 119 children (78 treated with collagenase, 41 with surgical debridement) with partial-thickness burn wounds established the safety and effectiveness of collagenase in children with a mean age of 3.2 AE 3 years, noting similar outcomes as those documented in adult studies and asserting that collagenase should be the treatment of choice for eschar removal in this population with burn injury. Use of collagenase in the neonatal population was first documented in two cases by Tiras et al (11) . The case series suggested that collagenase use was associated with expedient eschar removal, enhancement of granulation tissue formation, and prevention of scar formation. Erdeve et al (12) noted positive results in the treatment of thrombotic necrosis of the second digit of a neonate, negating the need for surgical intervention. Karagol et al (13) documented use of the enzymatic ointment for necrotic tissue removal of a wound on the pinna of the ear in a preterm neonate with a significant medical history.
Collagenase is the enzymatic debridement product of choice, in lieu of surgical intervention, in individuals with wounds containing yellow slough or eschar with significant bacterial bioburden (3, 4) . Individuals who are not candidates for surgical intervention can include those who are extremely medically fragile or undergoing anticoagulant therapy (3, 4) . Many babies in the neonatal intensive care unit (NICU) are medically fragile and may be undergoing anticoagulant therapy. At Arkansas Children's Hospital, when the previously listed conditions are present, collagenase is routinely considered, and the method of choice for physical therapists performing wound care in the NICU, with appropriate approval and an order from a licensed independent practitioner. The purpose of this retrospective case series was to examine the effectiveness of collagenase in the treatment of chronic or necrotic wounds in five patients (with six wounds) in the NICU.
METHODS

Patient Population
Before starting the study, permission was received from the University of Arkansas for Medical Sciences Institutional Review Board and the director of the NICU. An initial screen of medical records for NICU admissions for a 1-year period was conducted. A chart review was performed on five patients who presented with nonhealing wounds treated with collagenase during their admission to the NICU at Arkansas Children's Hospital. A total of six wounds were identified: five surgical wound dehiscence and one intravenous infiltrate. Each patient had a complex medical history and required close monitoring in the NICU. Table 1 presents demographic data and other infant characteristics.
Intervention
During the NICU admission, a physical therapist assessed and performed wound care, including application of collagenase (2 mm thickness), a moist cover layer (saline-soaked or petroleum-impregnated gauze) to achieve enzymatic activation for optimal results (8) , and adherent dressing (transparent adhesive film, tape, or self-adherent soft silicone dressing). Dressings containing silver or iodine were avoided because they inactivate collagenase (8) . For some patients, once debridement was complete, the collagenase was discontinued and an alternative dressing was applied.
Data Collection
Wound size (length, width, depth) and percentage of granulation tissue in the wound bed were assessed at each treatment. Initial wound measurements (Table 1 ) reflect the size of the wound when collagenase was initiated. Data collection included the number of days of an alternative debridement treatment or dressing and the number of days to full granulation tissue once the collagenase was applied. Total numbers of treatments are reported in Table 2 . Pain assessments (mean values reported in Table 2 ) were completed at each treatment, using the Neonatal Pain and Sedation Scale or the Revised Face, Legs, Agitation, Cry, Consolability Scale, depending on the patient's adjusted age and cognitive capability. Both scales have been shown to be reliable and valid in assessing pain in their studied population (14, 15) .
RESULTS
The mean age for assessed infants and neonates was 65.8 days. Chronological and adjusted ages are shown in Table 1 . Before the use of collagenase, five of the six wounds had been treated with an alternative dressing. None of the patients included in this review were being actively treated or had been treated with antibiotics for wound infection. Table 2 presents a summary of wound care treatment and the number of days to 100% granulation once the collagenase was applied. Full closure was obtained in five of the six wounds; patient 2 was discharged from the NICU before reaching closure. The number of days to reach Pain reported is an average over the treatment episode (Neonatal Pain and Sedation Scale or Revised Face, Legs, Agitation, Cry, Consolability Scale). *Patient 2 was discharged from the hospital before attaining 100% granulation; 90% achieved granulation by the seventh collagenase treatment.
100% granulation for the five wounds followed through full closure was 5 to 18 days (mean 12.2 days). Figure 1 provides a graph of the time course of wound healing for each patient once the collagenase was applied.
DISCUSSION
This retrospective study is similar to the case series of Tiras et al (11) , who suggested that collagenase use was associated with expedient eschar removal and enhancement of granulation tissue formation. All of the infants and neonates reviewed in the case series achieved full healing without the need for surgical intervention, which is similar to the case described by Erdeve et al (12) . Each of the patients in this study had multiple diagnoses and significant medical status changes throughout their hospital stays. Oxygenation levels, circulatory compromise, and overall nutrition can play a significant role in wound healing. Lack of oxygenation, tissue perfusion, and good nutrition can limit wound healing (5) . For instance, in patient 4 there was an apparent decline and plateau in improvement of wound A, which correlated with a period of significant medical status decline. The remaining four patients maintained a stable medical status throughout wound treatment and thus had a positive progression rate from the initial to the final treatment.
Daily wound care was completed with negligible pain recordings. Patients 4 and 5 had higher average pain scores (0.6 and 0.35, respectively) than patients 1, 2, and 3 (0), although these pain ratings were noted to be related to possible medication withdrawal or other medical procedures completed simultaneously with standard wound care.
Complete granulation was achieved in five of the six wounds addressed in this study; patient 2 was discharged before achieving 100% granulation, although she returned for follow-up 2 months later with a closed wound and minimal scar tissue formation at the wound site. The remaining five wounds were followed through complete healing. Patient 4's wound B was also treated with collagenase despite having reached 95% granulation, for uniformity of wound dressings.
Five of these wounds were treated with an alternative dressing before initiation of collagenase. Alternative therapies and products used before collagenase included wet to dry dressings, xeroform, adaptic, and various forms of cover dressings (foam, dry gauze, transparent film). Once collagenase was started, three of these wounds reached complete granulation and closure in less time than the total number of days the initial intervention had been used. Patients 3, 4, and 5 were treated with an alternative dressing once 100% granulation was achieved. Additional wound care studies are needed in infants and to examine the efficacy and cost of continuing collagenase as the primary dressing once 100% granulation has been achieved. The results of our retrospective study suggest that the use of collagenase for enzymatic debridement can be beneficial for the treatment of chronic and necrotic wounds in medically fragile infants. In addition, surgical intervention for the debridement and closure of these wounds was not required, providing cost savings and promoting a safer environment for the patient.
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